Pharmaceutical

CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody; binds to unique CD38 epitopeAMR is a leading cause of kidney transplant...

Ambulatory EHR Excellence 2026: Top Vendors Recognized for Breakthrough Innovation and Specialty User Satisfaction in Black Book 2026 Surveys

ModMed, Epic, NextGen Healthcare, Netsmart, athenahealth, and Specialty Category Innovators Lead Black Book's 2026 Ambulatory EHR Rankings NEW YORK CITY,...

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma targets a portion of the estimated $362 billion global solid tumor market Preliminary, unaudited cash balance of approximately...

error: Content is protected !!